SIK2 and ovarian cancer: Several studies have demonstrated that SIK2 is a centrosome kinase involved in mitosis regulation by facilitating centrosome separation during the G2 phase, and preclinical studies have reported the impact of SIK2 depletion in boosting the sensitivity of ovarian cancer cells to paclitaxel treatment [9,10,12].